Results 51 to 60 of about 329,096 (211)

Renal atrophy following gated delivery of stereotactic ablative radiotherapy to adrenal metastases

open access: yesPhysics and Imaging in Radiation Oncology, 2021
Stereotactic ablative radiotherapy (SABR) planning for adrenal metastases aims to minimize doses to the adjacent kidney. Renal dose constraints for SABR delivery are not well defined.
John R. van Sörnsen de Koste   +6 more
doaj   +1 more source

Hypervision Proton Surgery: The Future Direction of Proton Therapy

open access: yesiNew Medicine, EarlyView.
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley   +1 more source

Stereotactic centralized ablative radiation therapy: a framework for ultra-heterogeneous radiotherapy of bulky tumors

open access: yesFrontiers in Oncology
Bulky tumors remain difficult to treat because their size, irregular geometry, proximity to organs at risk, and heterogeneous microenvironment often conflict with standard radiotherapy objectives.
Jun Yang   +14 more
doaj   +1 more source

Intrafraction motion and impact of margin reduction for MR‐Linac online adaptive radiotherapy for pancreatic cancer treatments

open access: yesJournal of Medical Radiation Sciences, Volume 72, Issue 1, Page 17-24, March 2025.
This analysis included quantification of intrafraction motion in pancreas stereotactic ablative radiotherapy treated on the MR‐Linac, leading to the development of adjusted (PTV) margins. Intrafraction motion indicated an average target displacement of 1–3 mm, resulting in an adjusted PTV margin of 2 mm in the right–left and superior–inferior ...
Ashleigh Fasala   +6 more
wiley   +1 more source

Definitive single fraction stereotactic ablative radiotherapy for inoperable early-stage breast cancer: A case report

open access: yes, 2020
We review a case of inoperable early stage breast cancer treated definitively with the use of stereotactic ablative radiotherapy (SABR). A 57-year-old female with a history of decompensated cirrhosis with early stage breast cancer was treated with 25 Gy ...
Kim, Thomas; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, 60612, United States   +3 more
core   +1 more source

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours

open access: yes, 2012
Stereotactic ablative body radiotherapy (SABR) represents a technological breakthrough in radiotherapy technique, with proven benefits to patients in terms of improved tumour control and overall survival. The key components of SABR are described.
Goldsmith, Christy, Gaya, Andrew
core   +1 more source

Comment on “PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer”

open access: yesClinical and Translational Radiation Oncology
The recently published study by Zang et al. offers valuable insight into PSMA-PET/CTbased response assessment in patients with oligometastatic prostate cancer (PCa) undergoing stereotactic ablative body radiotherapy (SABR), demonstrating an impressive 5 ...
Parth Aphale   +2 more
doaj   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo   +4 more
wiley   +1 more source

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer

open access: yesCancer Management and Research, 2021
Davide Franceschini,1 Maria Ausilia Teriaca,1 Luca Dominici,1 Ciro Franzese,1,2 Marta Scorsetti1,2 1Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Milan, Italy; 2Department of Biomedical Sciences, Humanitas University ...
Franceschini D   +4 more
doaj  

C–X–C Motif Chemokine Receptor 4 (CXCR4)‐Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited‐Stage Small Cell Lung Cancer

open access: yesPrecision Radiation Oncology, EarlyView.
A newly proposed proton spatially fractionated radiotherapy guided by biological imaging Abstract Background and Purpose To evaluate the feasibility and dosimetric safety of integrating C–X–C motif chemokine receptor 4 (CXCR4)‐targeted tracer 18F‐AlF‐NOTA‐QHY‐04 positron emission tomography imaging with biologically guided proton spatially fractionated
Keru Pu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy